655 related articles for article (PubMed ID: 33371848)
1. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
2. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
Akilesh SM; J R; Palanisamy D; Wadhwani A
Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
[TBL] [Abstract][Full Text] [Related]
3. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
[TBL] [Abstract][Full Text] [Related]
4. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
5. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
6. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Watashi K
Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
[TBL] [Abstract][Full Text] [Related]
7. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
8. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
11. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Brest P; Benzaquen J; Klionsky DJ; Hofman P; Mograbi B
Autophagy; 2020 Dec; 16(12):2267-2270. PubMed ID: 32521191
[TBL] [Abstract][Full Text] [Related]
12. Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.
Batalha PN; Forezi LSM; Lima CGS; Pauli FP; Boechat FCS; de Souza MCBV; Cunha AC; Ferreira VF; da Silva FC
Bioorg Chem; 2021 Jan; 106():104488. PubMed ID: 33261844
[TBL] [Abstract][Full Text] [Related]
13. Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach.
Marak BN; Dowarah J; Khiangte L; Singh VP
Drug Dev Res; 2021 May; 82(3):374-392. PubMed ID: 33170521
[TBL] [Abstract][Full Text] [Related]
14. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
15. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
16. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
17. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
18. COVID-19: Discovery, diagnostics and drug development.
Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF
J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
[TBL] [Abstract][Full Text] [Related]
20. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.
Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ
Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
